Patheon has opened a new Pharmaceutical Development Services (PDS) suite at its Whitby Development Center in Canada for the small-scale development and manufacturing of solid dosage forms for early clinical studies.
The 2,500-sq.-ft. suite, as well as the facility, are GMP-compliant for manufacturing products for Phase I and II clinical studies. The suite will contribute to Patheon's Quick To Clinic offering for First Time in Human (Phase I) studies. The new facility will also add early-phase pharmaceutical development and manufacturing capacity, with a manufacturing scale of 1kg to 10kg. The suite has multiple labs with the capability for small-scale dosage form development, as well as the manufacture of powder-in-bottle, tablets (immediate and modified release), capsules, oral liquids, and nasal sprays.
Colin Minchom, Ph.D., vice president, PDS, Canada, said, "We're very excited about the rapid response capabilities of the new Whitby suite. This new facility will significantly strengthen Patheon's competitiveness in the pharmaceutical and biotechnology early development arena."
Terry Novak, president, North America and chief marketing officer, added, "Patheon is committed to investing in its development services business and with this new capacity in Whitby; we can now offer rapid early phase development to our North American customers."